A deeper dive into OIG’s new guidance and its impact on your
Compliance Adherence Practices. Learn how to best leverage the OIG
Compliance Guide in light of the DOJ Evaluation of Corporate
Compliance Programs.
The FDA set 5 standards for what is “Clear, Conspicuous, and
Neutral” for direct-to-consumer ads in a newly issued guidance, this
session will educate you on all aspects of the guidance requirements
to prepare for the November 2024 deadline.
Keep up with the constant changes in the state laws. This session
will provide a review of the 2024 passed legislations as well as
introduced proposed legislations.
In light of CMS’ new effort to audit Pharmaceutical companies, you
should be aware of some of the pitfalls that could potentially cost
major fines. This session is a practical way of analyzing your
Aggregate Spend Data to ensure compliance.
The CCPA changed the privacy landscape forever, with over a dozen
states following suit, and many more to come. Learn the similarities
and differences of these consumer data acts, and how companies are
handling them.
About half the states require some form of drug price transparency,
with each one setting their own threshold for reporting. This
session will walk you through the nuances so you know when (and when
not) to report.
Unlock new perspectives from this session that aims to deliver
excellence through shared knowledge as a panel of compliance
officers discuss the hottest topics.
